RhumbLine Advisers
CRSP icon

RhumbLine Advisers’s CRISPR Therapeutics CRSP Stock Holding History

RhumbLine Advisers’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.63M Buy
121,511
+6,689
+6% +$353K 0.01% 1320
2026
Q1 		$5.46M Sell
114,822
-3,956
-3% -$209K ﹤0.01% 1362
2025
Q4 		$6.23M Sell
118,778
-5,129
-4% -$307K 0.01% 1283
2025
Q3 		$8.03M Buy
123,907
+14
+0% +$804 0.01% 1187
2025
Q2 		$6.03M Buy
+123,893
New +$4.79M 0.01% 1318

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

RhumbLine Advisers's CRSP Position: Q2 2026 in Review

RhumbLine Advisers increased its CRISPR Therapeutics (CRSP) stake by 5.8% in Q2 2026, buying an estimated $353K and bringing the position to 121,511 shares worth $6.63M. The position accounts for 0.01% of the portfolio, ranked #1320.

RhumbLine Advisers first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. The position peaked at $8.03M in Q3 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • RhumbLine Advisers held 121,511 shares of CRISPR Therapeutics worth $6.63M as of Q2 2026.
  • RhumbLine Advisers bought 6,689 CRISPR Therapeutics shares in Q2 2026, an estimated $353K.
  • CRISPR Therapeutics made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1320 holding.
  • RhumbLine Advisers first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • RhumbLine Advisers's CRISPR Therapeutics position peaked at $8.03M in Q3 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.